Global Point-of-Care Testing Market Forecasted to Grow to over $18.7 Billion by 2011 While Outpacing Overall In Vitro Diagnostics Market.HUNTINGTON BEACH, Calif. -- According to a new InteLab Corporation industry report distributed by Life Science Intelligence (LSI LSI: see integrated circuit. (Large Scale Integration) Between 3,000 and 100,000 transistors on a chip. See SSI, MSI, VLSI and ULSI. ), the worldwide Point-of-Care Testing point-of-care testing Lab medicine The analysis of clinical specimens as close as possible to the Pt, including bedside, ward–unit, or 'stat' regional response labs that service specified areas–eg, the ER or ICU (POCT POCT Point of care testing, see there ) market is outpacing the overall In Vitro Diagnostics In vitro diagnostic (IVD) tests are medical tests conducted in a test tube, or more generally in a controlled environment outside a living organism. In vitro means in glass in Latin. market at a significant rate. Several companies are capitalizing on this growth, including Inverness, Biosite, Cholestech, and HemoSense. Each of these companies has recently been involved in acquisitions, further demonstrating the growing value of suppliers in this market. The report, "Worldwide Markets and Emerging Technologies for Point-of-Care Testing," forecasts the market to grow from $10.3 billion in 2005 to $18.7 billion by 2011. The report segments the market into three primary areas including hospital bedside testing products, home and self-testing products, and physician's office lab products. Several factors driving growth are analyzed including physician demands for more efficient testing approaches, availability of new biosensor A device that detects and analyzes body movement, temperature or fluids and turns it into an electronic signal. See lab on a chip and data glove. Biosensor technologies and computers systems, and an increased adoption of self-testing products by individuals. The study also discusses the significant and growing demand for diagnostic technologies that can allow more rapid and effective diagnosis and triage triage Division of patients for priority of care, usually into three categories: those who will not survive even with treatment; those who will survive without treatment; and those whose survival depends on treatment. , and that lead to improved patient outcomes and reduced health care costs. Notable high-growth segments analyzed in the study include POC (Proof Of Concept) See PoC exploit. POC - Point Of Contact cardiac markers, hospital POC glucose testing, coagulation coagulation (kōăg'y  lā`shən), the collecting into a mass of minute particles of a solid dispersed throughout a liquid (a sol), usually followed by the precipitation or self-testing, and home
cholesterol and drugs-of-abuse testing.
The global market study contains 429 pages, 124 exhibits, and coverage of nearly 100 competitors including Abaxis, Abbott, Accumetrics, Adaltis, Axis-Shield, Bayer Diagnostics/Siemens Medical, Beckman Coulter, BD, Biosite, Cepheid, Cholestech, Dexcom, Helena Labs, Hemocue, Hemosense, Thoratec, Inverness Medical Innovations, Medtronic Blood Management, Menarini Diagnostics, Nanogen, OraSure Technologies, Ortho Clinical Diagnostics/LifeScan, Phamatech, Princeton BioMeditech, Qualigen, Quidel, Radiometer radiometer (rā'dēŏm`ətər), instrument for detection or measurement of electromagnetic radiation; the term is applied in particular to devices used to measure infrared radiation. , Response Biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. , Roche Diagnostics, and Spectral Diagnostics. Key Topics * Trends in the global clinical diagnostics market and market analysis by segment * Factors driving growth in point-of-care testing * Hospital POC testing market analysis, including critical care testing, bedside whole blood glucose monitoring blood glucose monitoring Sugar monitoring Lab medicine The periodic testing of serum glucose in Pts known to have DM. See Bedside glucose monitoring, Beta cell implants, Diabetes, Glucometer, Glycosylated hemoglobin, Non-Invasive glucose monitoring. , rapid tests, POC coagulation testing, POC cardiac markers, and drugs of abuse rapid tests * Self-testing market assessment, including whole blood glucose monitoring, coagulation self-testing, pregnancy and fertility testing, home infectious disease and drugs of abuse testing, and home cholesterol testing * Physician's office laboratory market analysis by segment * Current and Forecast Market Size, Pricing Trends, and Analysis of Competitive Factors * Key business transactions, competitor strategies, and technology portfolio analysis Additional details at http://lifescienceintelligence.com/emt/reports/point-of-care/ or by calling 714 847 3540. About Life Science Intelligence Life Science Intelligence (LSI) delivers high quality market data and information to medical technology executives, entrepreneurs and investors. LSI produces the Emerging Medical Technology Database and provides custom research services including market assessments and physician surveys. In addition, the company partners with top tier information and consulting companies to distribute other high end information products. Learn more at www.lifescienceintelligence.com. About InteLab Corporation InteLab Corporation has served the needs of clients in the medical device and diagnostics industry worldwide since 1991. The company has published market studies covering numerous topics in the medical device and diagnostics industry, and has also performed proprietary market and technology assessments for a wide variety of medical product manufacturers worldwide. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion